Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource, 1 online resource.
- Language
-
Englisch
- Bibliographic citation
-
Results From a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis ; volume:9 ; number:2 ; day:19 ; month:4 ; year:2023 ; pages:237-253 ; date:6.2023
Pulmonary therapy ; 9, Heft 2 (19.4.2023), 237-253, 6.2023
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s41030-023-00222-2
- URN
-
urn:nbn:de:101:1-2023091012071198001724
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:57 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Mirsaeidi, Mehdi
- Baughman, Robert P.
- Sahoo, Debasis
- Tarau, Eva
- SpringerLink (Online service)
Other Objects (12)
Repository corticotropin for Chronic Pulmonary Sarcoidosis
Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation
Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases
A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
Sarcoidosis
Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
Repository corticotropin for Chronic Pulmonary Sarcoidosis
Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation
Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases
A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
Sarcoidosis
Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model
Repository corticotropin for Chronic Pulmonary Sarcoidosis
Repository Corticotropin Injection for the Treatment of Pulmonary Sarcoidosis: A Narrative Review
Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Correction to: Repository Corticotropin Injection for Persistently Active Systemic Lupus Erythematosus: Results from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Post Hoc Biomarker Analyses from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar® Gel) for Persistently Active Systemic Lupus Erythematosus
Repository Corticotropin in Treating de novo C3 Glomerulonephritis after Transplantation
Efficacy and tolerability of subcutaneous repository corticotropin injection in refractory ocular inflammatory diseases
A Narrative Review of Repository Corticotropin Injection for the Treatment of Systemic Lupus Erythematosus
Repository Corticotropin Injection for Active Rheumatoid Arthritis Despite Aggressive Treatment: A Randomized Controlled Withdrawal Trial
Sarcoidosis